This response provides a rationale for gemcitabine resistance in DLBCL cells, which can be reversed by attenuating the DNA-repair inducing pathway with an ATR (ataxia telangiectasia and Rad3-related protein) inhibitor, and thereby re-establishing gemcitabine sensitivity. This evidence concerns the gene ATR and diffuse large B-cell lymphoma.